RxDoctor Payments Data

Khurram Butt, MD

Internal Medicine · Dennison, OHNPI 1437149176

Payments from drug & device makers

$668in general payments, 2019–2025

Across 37 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$168
  • Lilly USA, LLC$94
  • Sanofi-aventis U.S. LLC$85
  • Medtronic$74
  • Abbott$46
  • AstraZeneca$34
  • plus $168 from 8 others

What the payments were for

  • Food & beverage$668100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$668 in reported general payments places this provider in the 70th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$41,052
Medicare patients
142
Services billed
641

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate84$66,824
TrulicityDulaglutide31$51,407
EliquisApixaban51$38,355
Combivent RespimatIpratropium/Albuterol Sulfate57$32,751
OzempicSemaglutide31$30,520
JardianceEmpagliflozin36$27,231
MounjaroTirzepatide12$17,316
Tresiba Flextouch U-100Insulin Degludec31$16,513
XareltoRivaroxaban28$14,806
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$13,564
MyrbetriqMirabegron13$10,003
FarxigaDapagliflozin Propanediol12$9,849
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$7,376
Fiasp FlextouchInsulin Aspart (Niacinamide)12$6,540
TradjentaLinagliptin12$6,404

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$94$68,72343 claims
MerckJanuvia$26$66,82484 claims
Boehringer IngelheimCombivent Respimat, Jardiance, Tradjenta$25$66,386105 claims
PfizerEliquis$17$38,35551 claims
Novo NordiskOzempic$168$30,52031 claims
AstraZenecaFarxiga, Symbicort$34$13,38128 claims
Sanofi-aventis U.S. LLCLantus$85$1,83414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Dennison

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →